Fulltext

Lipid Profiles in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Are Different Antiretroviral Drugs Associated with Different Lipid Profiles?

Fontas, E. ; van Leth, F. ; Sabin, C. A. ; Friis-Møller, N. ; Rickenbach, M. ; d'Arminio Monforte, A. ; Kirk, O. ; Dupon, M. ; Morfeldt, L. ; Mateu, S. ; Petoumenos, K. ; El-Sadr, W. ; de Wit, S. ; Lundgren, J. D. ; Pradier, C. ; Reiss, P.

In: The Journal of Infectious Diseases, 2004, vol. 189, no. 6, p. 1056-1074

Ajouter à la liste personnelle
    Titre
    • Lipid Profiles in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Are Different Antiretroviral Drugs Associated with Different Lipid Profiles?
    Auteur
    • Fontas, E.. 1Nice Cohort, Infectious Diseases Department, Nice University Hospital, Nice
    • van Leth, F.. International Antiviral Therapy Evaluation Center,AIDS Therapy Evaluation Project Netherlands Study Group and Department of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    • Sabin, C. A.. Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
    • Friis-Møller, N.. Data Collection on Adverse Events of Anti-HIV Drugs Study Coordinating Centre, Copenhagen HIV Programme, Hvidovre University Hospital, Copenhagen, Denmark
    • Rickenbach, M.. Swiss HIV Cohort Study, Division of Epidemiology, Centre Hospitalier Universitaire (CHU) Vaudois, University of Lausanne, Lausanne, Switzerland
    • d'Arminio Monforte, A.. Italian Cohort of Naive for Antiretrovirals, Department of Infectious Diseases, L. Sacco Hospital, University of Milan, Milan, Italy
    • Kirk, O.. EuroSIDA, Copenhagen HIV Programme, Hvidovre University Hospital, Copenhagen, Denmark
    • Dupon, M.. 2Aquitaine, Section Biostatistique, Bordeaux University Hospital, Bordeaux, France
    • Morfeldt, L.. HivBivus, Department of Infectious Diseases, Karolinska Hospital, Stockholm, Sweden
    • Mateu, S.. Barcelona Antiretroviral for Surveillance Study, Department of Clinical Pharmacology and Therapeutics, Autonomous University of Barcelona, Barcelona, Spain
    • Petoumenos, K.. Australian HIV Observational Database, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    • El-Sadr, W.. Community Programs for Clinical Research on AIDS, Division of Epidemiology, Columbia University School of Public Health, New York, New York
    • de Wit, S.. Brussels St. Pierre Cohort, Department of Infectious Diseases, CHU Saint Pierre Hospital, Brussels, Belgium
    • Lundgren, J. D.. Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
    • Pradier, C.. 1Nice Cohort, Infectious Diseases Department, Nice University Hospital, Nice
    • Reiss, P.. AIDS Therapy Evaluation Project Netherlands Study Group and Department of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • The Journal of Infectious Diseases, 2004, vol. 189, no. 6, p. 1056-1074. The University of Chicago Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:293706
    Summary
    Levels of triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), and high-density lipoprotein cholesterol (HDL-c), as well as the TC:HDL-c ratio, were compared in patients receiving different antiretroviral therapy regimens. Patients receiving first-line regimens including protease inhibitors (PIs) had higher TC and TG levels and TC:HDL-c ratios than did antiretroviral-naive patients; patients receiving 2 PIs had higher levels of each lipid. Ritonavir-containing regimens were associated with higher TC and TG levels and TC:HDL-c ratios than were indinavir-containing regimens; however, receipt of nelfinavir was associated with reduced risk of lower HDL-c levels, and receipt of saquinavir was associated with lower TC:HDL-c ratios. Patients receiving nonnucleoside reverse-transcriptase inhibitors had higher levels of TC and LDL-c than did antiretroviral-naive patients, although the risk of having lower HDL-c levels was lower than that in patients receiving a single PI. Efavirenz was associated with higher levels of TC and TG than was nevirapine